1 / 17

Cerebral Venous Thrombosis

Cerebral Venous Thrombosis. Department of Neurosciences Canberra Hospital March 1999. Cerebral Venous Thrombosis.

paul-mcintyre
Download Presentation

Cerebral Venous Thrombosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cerebral Venous Thrombosis Department of Neurosciences Canberra Hospital March 1999

  2. Cerebral Venous Thrombosis • Rare and severe disease characterised clinically by headache, papilledema, seizures, focal deficits, coma and death; pathologically by hemorrhagic infarction often contraindicating anticoagulation.

  3. HISTORICAL BACKGROUND • Ribes 1825 • 45 yo man • 6 months severe headache, epilepsy and delirium. • Postmortem: superior sagittal sinus, left lateral and left parietal cortical vein thrombosis • Abercrombie 1828 • Postpartum cerebral venous thrombosis

  4. INCIDENCE • Unknown incidence • Increased frequency of diagnosis since advent of DSA, CT & MRI/V. • Ehlers & Courville 1936 • 16 sagittal sinus thrombosis in 12500 autopsies • Kalbag & Woolf • 21.7 deaths per year in England & Wales from 1952 – 1961. • Male/female ratio = 1.29/1 • Males uniform age distribution • Females 61% CVT in 20-35 age group

  5. FREQUENCY OF VENOUS SITES(OFTEN MULTIPLE) • Superior sagittal sinus 72% • Lateral sinus 70% • Right 26% • Left 26% • Both 18% • Straight sinus 14.5% • Cavernous sinus 2.7% • Cerebral veins 38% • Superficial 27% • Deep 8% • Cerebellar veins 3%

  6. FREQUENCY OF VENOUS SITES(SINGLE SITE) • One sinus only 23% • Superior sagittal sinus 13% • Lateral sinus 9% • Straight sinus 1% • Deep veins only 1% • Isolated cortical veins 1%

  7. ETIOLOGY • IDIOPATHIC • INFECTIVE • Local: direct septic trauma • Intracranial infection • Regional infection • General: Septicemia, measles, encephalitis, HIV, CMV, malaria • NONINFECTIVE • Local: head injury, neurosurgery, tumors, infusions into jugular vv • General: Postoperative, pregnancy/postpartum, dehydration, inflammatory bowel disease, connective tissue disease, malignancy, thrombophilia.

  8. CLINICALLY BY SYNDROMIC DESCRIPTION • 1.Isolated intracranial hypertension 40% • mimic benign intracranial hypertension • 2.Focal signs 50% • 3.Cavernous sinus thrombosis • 4.Unusual presentations • Psychiatric disturbances, migraines, subarachnoid hemorrhages.

  9. CLINICALLY BY SYMPTOMATOLOGY • Headache 75% • Papilledema 49% • Motor or sensory deficit 34% • Seizures 37% • Drowsiness, mental changes, confusion, or coma 30% • Dysphasia 12% • Multiple cranial nerve palsies 12% • Cerebellar incoordiantion 3% • Nystagmus 2% • Hearing loss 2% • Bilateral or alternating cortical signs 3%

  10. INVESTIGATIONS – DIAGNOSTIC • .CT • Infarction in nonarterial distribution (often hemorrhagic) • Empty delta sign • Dense triangle sign • Cord sign • .DSA • .MRI/V • Early: absence of flow void & isointense on T1 for occluded vessel; Hypointense on T2 • Late:hyperuintense thrombus on T1 & T2 • .CRANIOTOMY • OTHERS: EEG, CSF, isotope brain scanning.

  11. INVESTIGATIONS – ETIOLOGIC • FBE • ANA, antiphospholipid antibodies • APC resistance (Factor V Leiden) • Antithrombin • Protein C, S • Homocysteine • Prothrombin gene mutation • Repeat tests in 4-6 months.

  12. TREATMENT • 1.Infective cause • 2.Increased intracranial pressure • 3.Anticoagulation: • initially heparin • warfarin (?duration) • direct urokinase infusion

  13. PROGNOSIS • MORTALITY • Untreated: 50% • Treated: nonseptic cause 10% • septic cause 30% • OUTCOME • 77% no sequelae • 20% develop thrombosis intra or extracerebrally • Longest followup study is 8 yrs.

  14. SUMMARY • Uncommon but life threatening disease. • Mimic many benign conditions. • Untreated carries 50% mortality. • If treated, majority of patients have no long term disability. • An underlying cause should always be sought.

  15. THROMBOPHILIA & CEREBRAL VENOUS THROMBOSIS • 25% CVT have a detectable thrombophilia (APC resistance; antithrombin, protein C or S deficeincy, antiphospholipid syn) • 20% CVT have APC resistance • 95% APC resistance due to Factor V leiden. • In patients with CVT attributable to APC resistance, • 72% had a second contributing factor (OCP, other thrombophilia) • Contribution of G20210A prothrombin gene mutation unknown.

  16. ORAL CONTRACEPTIVE PILL AND CVT • Relative risk of developing CVT • OCP RR13 • Thrombophilia RR4 • OCP & Thrombophilia RR30 • De Bruijn et al. Case control study of risk of cerrebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions. BMJ 1998: 316, 589-92.

  17. ISSUES • APC resistance is not always caused by Factor V Leiden. • Different thrombogenicity of second vs third generation OCP. • Contribution of G20210A prothrombin gene mutation to CVT.

More Related